Division of General Internal Medicine
Evidence-Based Medicine
Table of Contents
Clinical Prediction
Rules
Peer Reviewed Summaries
(Mount Sinai Intranet Only)
Clinical Calculators
Therapeutic NNT and NNS
EBM Web Sites

Created by: Carlton Moore, Thomas McGinn, Warren Ho






















































Clinical Prediction Rules

Select Category
Methodological Standards
for Evaluating CPRs
Levels of Evidence
Cardiovascular Respiratory
Endocrine/Metabolic Orthopedics
InfectiousDiseases All CPRs
Nephrology Screening
Procedures
CPRs for the Palm
 

Return to Table of Contents



















































Clinical Calculators
Return to Table of Contents
Metabolic Pulmonary Renal Statistics
Return to Table of Contents


















































Therapeutic NNT and NNS
Return to Main Table of Contents
Introduction:
The purpose of our Therapeutic NNT project is to critically examine the background data that drives our decision making in primary care. From experience we realize that primary care physicians are not always familiar with the data that supports everyday screening and therapy. Our goal is to investigate representative, randomized, placebo-controlled studies that justify our daily practices.

Created by: Tuvana Bain, Scott Liebman, and Thomas McGinn

Table of Contents
Cardiovascular Neurology
EndocrineScreening
Gastroenterology











Clinical Questions

Cardiovascular: CHF
  1. In patients with CHF, what is the mortality benefit of treating with an ACE inhibitor?
  2. In patients with CHF, is there a mortality benefit in treating with carvedilol?
  3. Does digoxin affect the mortality or morbidity rates in patients with CHF?
  4. What is the effect of adding spirinolactone to a traditional medical CHF regimen with respect to CV death and hospitalization?
Cardiovascular: CAD
  1. What is the magnitude of the effect of Beta-Blockers post-MI?
  2. In patients with CAD, how large is the effect of treating high cholesterol with simvastatin?
  3. In men with hypercholesterolemia, does treatment with pravastatin prevent coronary events?
  4. Is there a survival benefit in treating post MI patients with pravastatin for "average" cholesterol levels?
  5. In patients who are at high risk for CAD does ramipril prevent mortality from cardiovascular causes?
  6. Does treatment with estrogen and progestin decrease the rate of coronary death and nonfatal MI among postmenopausal women with established CAD?
  7. How effective is hypertension control in preventing MI's, strokes and CV deaths?
  8. Should aspirin be used as primary prevention for CAD in men?
Cardiovascular: Other
  1. What is the magnitude of the effect of stroke prevention of anti-coagulating patients with non-rheumatic atrial fibrillation (AF)?
Endocrine:
  1. What is the magnitude of the effect of intensive blood-glucose control in patients with Type II diabetes?
Neurology:
  1. Does gabapentin therapy offer symptomatic relief in patients with diabetic neuropathy?
Screening:
  1. What is the magnitude of the effect of screening for cervical cancer in women?
  2. What is the magnitude of the effect of screening for colon cancer in patients over age 50 with the fecal occult blood (FOB) test plus flexible sigmoidoscopy?
Return to Top
























 

EBM Web Sites


 

Medical InfoRetriever

MedRules

Bandolier   EBM Series

New York Academy of Medicine

Centre for Evidence-Based Medicine

Return